116 results about "Glucose monitors" patented technology

Systems and methods for integrating a continuous glucose sensor 12, including a receiver 14, a medicament delivery device 16, a controller module, and optionally a single point glucose monitor 18 are provided. Integration may be manual, semi-automated and / or fully automated.

A glucose monitoring device is provided. The glucose monitoring device includes a housing having a first portion and a second portion, the second portion operable to be placed adjacent to a human body during operation of the glucose monitoring device. The glucose monitoring device further includes a circuit board positioned between the first portion and the second portion of the housing, the circuit board having a trace antenna. The glucose monitoring device further includes a conductive structure spaced apart from the circuit board.

Systems and methods for integrating a continuous glucose sensor, including a receiver, a medicament delivery device, and optionally a single point glucose monitor are provided. Manual integrations provide for a physical association between the devices wherein a user (for example, patient or doctor) manually selects the amount, type, and / or time of delivery. Semi-automated integration of the devices includes integrations wherein an operable connection between the integrated components aids the user (for example, patient or doctor) in selecting, inputting, calculating, or validating the amount, type, or time of medicament delivery of glucose values, for example, by transmitting data to another component and thereby reducing the amount of user input required. Automated integration between the devices includes integrations wherein an operable connection between the integrated components provides for full control of the system without required user interaction.

Glucose prediction using machine learning (ML) and time series glucose measurements is described. Given the number of people that wear glucose monitoring devices and because some wearable glucose monitoring devices can produce measurements continuously, a platform providing such devices may have an enormous amount of data. This amount of data is practically, if not actually, impossible for humans to process and covers a robust number of state spaces unlikely to be covered without the enormous amount of data. In implementations, a glucose monitoring platform includes an ML model trained using historical time series glucose measurements of a user population. The ML model predicts upcoming glucose measurements for a particular user by receiving a time series of glucose measurements up to a time and determining the upcoming glucose measurements of the particular user for an interval subsequent to the time based on patterns learned from the historical time series glucose measurements.

A glucose monitoring system comprising a sensor control device comprising an analyte sensor coupled with sensor electronics, the sensor control device configured to transmit data indicative of an analyte level of a subject, and a reader device. The reader device comprises a wireless communication circuitry configured to receive the data indicative of the analyte level and a glycated hemoglobin level for the subject, a non-transitory memory, and at least one processor communicatively coupled to the non-transitory memory and the analyte sensor and configured: calculate a plurality of personalized glucose metrics for the subject using at least one physiological parameter and at least one of the received data indicative of the analyte level or the received glycated hemoglobin level, and a display, on a display of the reader device, a report comprising a plurality of interfaces including at least two or more of the received data indicative of the analyte level, the received glycated hemoglobin level, or the calculated plurality of personalized glucose metrics, wherein the plurality of interfaces comprising the report are based on a user type.

A system for monitoring glucose concentration that includes a sample holder configured to contain a sample and a radio frequency transmitter configured to emit microwave radiation through the sample. The radio frequency transmitter comprising a radio frequency generator and a first antenna. The radio frequency receiver is configured to receive microwave radiation transmitted from the radio frequency transmitter and passed through the sample, and convert the microwave radiation passed through the sample to an analog signal. The radio frequency receiver comprising a second antenna. The system also includes an analog readout circuit configured to receive the analog signal and process the analog signal into a modified analog signal, and a digital signal processing circuit configured to receive the modified analog signal, convert the modified analog signal into a digital signal, and determine the glucose concentration of the sample from the digital signal.

Exemplary embodiments may address the problem of missing blood glucose concentration readings from a glucose monitor that transmits blood glucose concentration readings over a wireless connection due to problems with the wireless connection. In the exemplary embodiments, an automated insulin delivery (AID) device uses an estimate in place of a missing blood glucose concentration reading in determining a predicted future blood glucose concentration reading for a user. Thus, the AID device is able to operate normally in generating insulin delivery settings despite not receiving a current blood glucose concentration reading for a current cycle. There is no need to suspend delivery of insulin to the user due to the missing blood glucose concentration reading.

Exemplary embodiments may address the problem of missing blood glucose concentration readings from a glucose monitor that transmits blood glucose concentration readings over a wireless connection due to problems with the wireless connection. In the exemplary embodiments, an automated insulin delivery (AID) device uses an estimate in place of a missing blood glucose concentration reading in determining a predicted future blood glucose concentration reading for a user. Thus, the AID device is able to operate normally in generating insulin delivery settings despite not receiving a current blood glucose concentration reading for a current cycle. There is no need to suspend delivery of insulin to the user due to the missing blood glucose concentration reading.

This disclosure describes a glucose monitor with one or more photonic crystal surface-emitting lasers (PCSELs). The PCSEL comprises a plurality of photonics crystal sections. Each photonics crystal section is operable to emit light of a different wavelength. The horizontal emission by each photonics crystal section may be constrained by edge lattice sections.

A glucose monitoring system includes a sensor control device comprising an analyte sensor coupled with sensor electronics, the sensor control device configured to transmit data indicative of an analyte level, and a reader device comprising a wireless communication circuitry configured to receive the data indicative of the analyte level, and one or more processors coupled with a memory. The memory is configured to store instructions that, when executed by the one or more processors, cause the one or more processors to: determine a frequency of interaction over a first time period based on one or more instances of user operation of the reader device, and output a first notification if the determined frequency of interaction is below a predetermined target level of interaction and output a second notification if the determined frequency of interaction is above the predetermined target level of interaction, wherein below the predetermined target level of interaction, an increase in the determined frequency of interaction corresponds to a first improvement in a metabolic parameter, and above the predetermined target level of interaction, an increase in the determined frequency of interaction corresponds to a second improvement in the metabolic parameter.

The present disclosure presents glucose monitoring systems and methods. One such system comprises a glucose monitoring sensor having at least a counter electrode, a reference electrode, and a working electrode; and a silicon-carbide-silicon-carbide-nanoparticles-electrospun-nanofibrous-membrane contacting the working electrode. The system further includes a glucose oxidase enzyme solution contacting the silicon-carbide-silicon-carbide-nanoparticles-electrospun-nanofibrous-membrane, wherein a conductive polymer membrane assists in binding the glucose oxidase enzyme composition with the silicon-carbide-silicon-carbide-nanoparticles-electrospun-nanofibrous-membrane. Other systems and methods are also provided.

This invention provides a precise control structure and applicator for the indwelling device in a continuous glucose monitoring (CGM) meter. By incorporating a clock structure consisting of an unlocking control track and a control block, different areas on the unlocking control track apply varying forces to the control block. These forces switch precisely upon completion of the puncture, allowing the clock structure to correlate with the puncture process. This enables the device to sense the puncture and promptly unlock the indwelling device after the procedure. This mechanical structure offers precise control and high integration, making it a glucose monitoring product that provides accurate control within a relatively small size.

Systems, computer programs, devices, and methods that enable coordination across multiple devices of the mobile ecosystem. In one embodiment, smart glasses detect when a user is about to eat food or take a drink and capture the consumable and portion. The data is recorded in a "morsel track" for health activity analysis. Low-fidelity captures provide preliminary recognition, while higher-fidelity captures are selectively invoked for definitive classification. Machine-learning logic generates predicted metabolic responses, such as real-time glucose trends, based on the recorded events. Predicted responses may dynamically adjust the operation of continuous glucose monitors, heart-rate sensors, or other biomedical devices. In some embodiments, the system triggers a pharmaceutical dispenser, such as an insulin pump, inhaler, or transdermal patch, to provide closed-loop therapeutic intervention in real time.

Glucose level measurements of a user are obtained over time, such as from a wearable glucose monitoring device being worn by the user. These glucose level measurements can be produced substantially continuously, such that the device may be configured to produce the glucose level measurements at regular or irregular intervals of time, responsive to establishing a communicative coupling with a different device, and so forth. These glucose level measurements are analyzed to detect deviations from past glucose measurements, such as glucose measurements received earlier in the day or glucose measurements received at corresponding times of one or more preceding days. Indications of detected deviations are provided to the user or communicated elsewhere, such as to a healthcare professional.

A glucose monitoring device is provided. The glucose monitoring device includes a housing having a first portion and a second portion, the second portion operable to be placed adjacent to a human body during operation of the glucose monitoring device. The glucose monitoring device further includes a circuit board positioned between the first portion and the second portion of the housing, the circuit board having a trace antenna. The glucose monitoring device further includes a conductive structure spaced apart from the circuit board.

Implantable device for measuring the glucose concentration of a body fluid when implanted, the device comprising a glucose measurement unit, the glucose measurement unit comprising a light source configured to emit light towards a light transmissive part of a housing of the device, the device further comprising an optical sensor configured to detect light returned through the transmissive part from the light source, and output an electrical signal based on the detected light, and a wireless communication module configured to wirelessly communicate with an external wireless communication device, wherein the wireless communication module is configured to wirelessly transmit a signal based on the electrical signal to the external wireless communication device.

A computer-implemented method for predicting a risk whether a hypoglycemic event will occur during a prediction time interval is disclosed. The method comprises: providing user values for a plurality of machine learning input parameters, the user values determined from glucose monitoring data with glucose measurement values detected for a user before a cut-off time, the plurality of machine learning input parameters comprising: at least one first glucose measurement value determined from glucose measurements values measured within at most 10 minutes before the cut-off time, and a hypoglycemic event share value indicative of a share of previous prediction time intervals with detected hypoglycemic events out of a total number of previous prediction time intervals before the cut-off time; predicting, based on the user values and using a machine learning model, a risk whether a hypoglycemic event will occur during a prediction time interval associated with assumed sleep of the user, the machine learning model generated based on the machine learning input parameters and using historical glucose monitoring data of a user population; and generating an output based on the predicted risk. Further, a data processing system, a computer program, a system, and a remote control are disclosed.

A transdermal glucose monitoring system is provided. The system includes: a continuous glucose monitoring (CGM) device, configured to monitor glucose concentration in subcutaneous interstitial fluid of a patient; a patient user interface, configured to acquire information of the CGM device, receive glucose concentration data, and display a warm-up progress indicator of the CGM device; and a cloud server, configured to complete data sharing and authorize access to data. The provided patient user interface focuses on the warm-up time of the CGM device and provides a positive and intuitive display thereof, along with visual management of glucose monitoring data analysis, thereby enhancing the convenience of glucose monitoring. Furthermore, the system supports a second monitoring device, enabling family and friends to promptly understand the patient's glucose monitoring status and infer the causes of glucose fluctuations.

The invention discloses a 3D nano microneedle electrode for improving glucose monitoring performance and a preparation method and application thereof, and relates to the technical field of biosensing. The 3D nanometer microneedle electrode for improving the glucose monitoring performance comprises a microneedle electrode base material and an electrode sensing material, the microneedle electrode base material is a stainless steel intradermal injection needle, the microneedle electrode base material is filled with a conductive filler, the conductive filler comprises carbon paste and silver paste, and the electrode sensing material comprises an inner layer structure and a surface layer structure. The inner-layer structure is a conductive nano-carrier, and the surface-layer structure is a compound enzyme layer. The invention also provides a preparation method of the 3D nano microneedle electrode for improving the glucose monitoring performance. The utilization rate and catalytic activity of Prussian blue are improved, electron transfer is accelerated, and the problems that a traditional glucose sensor is low in electron transfer efficiency, insufficient in stability and limited in detection range and accuracy are effectively solved.

An application running on a device to manage insulin site rotation may read a configuration file including a group, a plurality of sites in the group, and an image associated with the group. The application may detect an input selecting a site from the plurality of sites for administration of an insulin management device. The application may also set the selected site as unavailable for a predetermined duration in response to the input selecting the site. A log entry may be written to track usage of the site in response to the input selecting the site. A visual indicator on the selected site may show that the site is recently selected in response to detecting the input selecting the site within a predetermined duration. The insulin management device may be a pump, a syringe, or a glucose monitor.

Electrochemical impedance spectroscopy (EIS) is used in conjunction with continuous glucose monitors and continuous glucose monitoring (CGM) to enable in-vivo sensor calibration, total (sensor) failure analysis, and intelligent sensor diagnostics and failure detection. An equivalent circuit model is defined and each circuit element is used to characterize sensor behavior.

A personal diabetes equipment management system can include at least one diabetes treatment device adapted for use with one or more disposable diabetes devices; a remote server system including an inventory database identifying operational diabetes treatment devices and operational disposable diabetes devices in the possession of a user; and a controller in communication with (i) the at least one diabetes treatment device over a first network connection and (ii) the remote server system over a second network connection, the controller adapted to automatically detect use of the at least one diabetes treatment device and determine an operational condition for the diabetes treatment device or the one or more disposable diabetes treatment devices based on information received from the at least one diabetes treatment device over the first network connection, the controller transmitting update information to the remote server system over the second network connection to update the inventory database.

Methods, systems, and devices for evaluating a user's metabolic balance are described. A system may include a wearable device and a glucose monitoring device. The system may acquire physiological data from the wearable device, and blood glucose data from the glucose monitoring device. The system may be configured to determine physiological characteristics of the user based on the physiological data, such characteristics associated with a sleep quality of the user, a stress level of the user, an activity level of the user, a recovery of the user, or any combination thereof. Similarly, the system may identify metabolic characteristics of the user, such as changes in the user's blood glucose data. By overlaying and comparing the physiological data and the blood glucose data, the system may be able to evaluate how the user's physiological characteristics affect or impact the user's metabolic characteristics, or vice versa.

The present disclosure provides a system and a computer-implemented method of determining an insulin dosage to provide to a user. The computer-implemented method includes receiving glucose monitoring data from a glucose sensor. The glucose sensor is configured to gather glucose monitoring data from the user. The method also includes receiving mealtime data associated with a meal from a user device and determining based on the mealtime data whether the user plans to perform postprandial exercise. If the user plans to perform postprandial exercise, the method includes determining an exercise ratio using the multi-agent reinforcement learning module and calculating the insulin dosage using the glucose monitoring data, mealtime data and the exercise ratio. If the user does not plan to perform postprandial exercise, the method includes calculating the insulin dosage using the glucose monitoring data and mealtime data.

A compensation method for a continuous glucose monitor includes: acquiring a glucose value of a user continuously; determining a user type and a glucose trend type according to the glucose value, where the user type includes at least a first user type and a second user type; determining, based on the glucose value, whether a compensation start condition is satisfied;starting a compensation algorithm if the compensation start condition is satisfied; determining a compensation formula based on the glucose value and the glucose trend type; and obtaining, based on the glucose value and the compensation formula, a compensated glucose value until a compensation stop condition is satisfied.

A continuous analyte monitoring system includes first and second analyte sensors configured to sense analytes such as lactate and glucose in the tissue of a user. A controller Is coupled to the analyte sensors and configured evaluate first samples of outputs of the first analyte sensor and second samples of outputs of the second analyte sensor with respect to one another to determine whether the first samples and the second samples indicate compression of the tissue. If the first samples and the second samples indicate compression of the tissue, compensate for the compression of the tissue with respect to the first samples. The controller may evaluate the machine learning models using a machine learning model or a filter.

Embodiments described herein include glucose monitoring systems configured to use various methods and additional systems to facilitate communication of glucose data from data receiving devices that do not have wireless network capabilities. Certain embodiments facilitate communication of data to general purpose devices, user devices, and electronic medical record (EMR) systems. Certain embodiments facilitate communication of data to report generation systems that interpret the data and provide reports based on the glucose data. Certain embodiments relate to techniques for facilitating integration of EMR system data management and report generation.

The invention discloses an analysis model as well as a system and a method for applying the analysis model to multifunctional intelligent shoes for diabetes. The system comprises an intelligent shoe body, an intelligent terminal and a dynamic blood glucose monitor, the intelligent shoe body comprises a shoe body, a sole and an insole; the upper surface of the insole is divided into a plurality of sensing areas, and a pressure sensing module is arranged in each sensing area; a functional area is fixedly arranged on the shoe body, and a wireless module is installed in the functional area; the wireless module is electrically connected with each pressure sensing module through a connecting wire, and is wirelessly connected with the intelligent terminal and the dynamic blood glucose monitor. The intelligent terminal is provided with a blood glucose abnormal trend analysis model based on plantar pressure distribution, a long-short memory model is trained through subarea pressure distribution data according to different age groups, suspected and definite case data are analyzed from a test set, and therefore a distance model for distance definite diagnosis is constructed, and the function of early prevention of diseases is achieved.

Described herein are examples of systems and methods for determining the efficacy of a therapeutic intervention related to the treatment of diabetes. In an example, a continuous glucose monitor can be used to monitor the glucose levels of a subject. An insulin pump can administer insulin to the subject in response to the glucose levels obtained by the continuous glucose monitor. The efficacy of a treatment intervention can be determined by comparing an amount of insulin administered to the subject by the insulin pump over a timeframe associated with the treatment intervention to an amount of insulin administered to the subject by the insulin pump over a timeframe associated with a control or placebo period and / or a timeframe associated with a second treatment intervention.

The invention discloses a glucose monitoring probe and a preparation method thereof, the glucose monitoring probe comprises a working electrode, the working electrode is provided with a sensing layer, the sensing layer comprises glucolase and a redox polymer, and the redox polymer has a structure as shown in a formula (1): # imgabs0 #, a1 and A2 are the same and are selected from any one of 4-vinylpyridine and N-vinyl imidazole, and A3 is methacrylate quaternary ammonium salt. According to the invention, the glucose monitoring probe with high sensitivity and strong anti-interference capability and the preparation method thereof can be provided.